

Crohn's Disease Ulcerative Colitis

A study to look at the long-term safety of a medicine, efmarodocokin alfa, in people with ulcerative colitis

An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

Trial Status Terminated	Trial Runs In 14 Countries	Trial Identifier NCT03650413 2017-004997-32 GA40209
-----------------------------------	--------------------------------------	--

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This clinical trial was done to study a new medicine called, "efmarodocokin alfa", for the treatment of patients with ulcerative colitis. This was a Phase 2 open-label extension study to find out the long-term safety and tolerability of efmarodocokin alfa in patients with moderate to severe ulcerative colitis. It was carried out at 66 study centers in fourteen countries.

Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland) Sponsor	Phase 2 Phase
--	-------------------------

NCT03650413 2017-004997-32 GA40209
Trial Identifiers

Eligibility Criteria:

Gender All	Age >= 18 Years & <= 80 Years	Healthy Volunteers No
----------------------	---	---------------------------------
